This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent
adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of
platinum-based chemotherapy, and up to two additional cytotoxic regimens that may also have
included platinum (no more than four total lines of prior therapy), with or without
bevacizumab, whose cancer has recurred within six months of the most recent platinum-based
chemotherapy. All eligible subjects will receive VAL 083 i.v. in a once weekly cycle until
disease progression, development of other unacceptable toxicity, death, withdrawal of
consent, loss to follow-up, or Sponsor ending the study, whichever occurs first.
Phase 1/Phase 2
Estimated Primary Completion Date
- Drug: VAL-083, Dianhydrogalactitol
DelMar Pharmaceuticals, Inc.